Article
Genetic and proteomic features associated with survival after treatment with erlotinib in first-line therapy of non-small cell lung cancer in Eastern Cooperative Oncology Group 3503.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Feb 2010
Amann Joseph M, Lee Ju-Whei, Roder Heinrich, Brahmer Julie, Gonzalez Adriana, Schiller Joan H, Carbone David P
Abstract excerpt
INTRODUCTION: Serum proteomics and mutations in the epidermal growth factor receptor (EGFR) and KRAS have been associated with benefit after therapy with EGFR-targeted therapies in non-small cell lung cancer, but all three have not been evaluated in any one study. HYPOTHESIS: Pretreatment serum proteomics predicts survival in Western advanced non-small cell lung cancer patients with wild-type EGFR and independent...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.